Pharmaceutical - Novo Nordisk, Diabetes

Filter

Current filters:

Novo NordiskDiabetes

Popular Filters

1 to 25 of 101 results

Novo Nordisk and Karolinska Institutet collaborate on diabetes postdoctoral research program

Novo Nordisk and Karolinska Institutet collaborate on diabetes postdoctoral research program

10-02-2015

Danish insulin giant Novo Nordisk is to join forces with Swedish researchers Karolinska Institutet for…

DenmarkDiabetesNovo NordiskPharmaceuticalResearchSweden

Strong sales and earnings growth for Novo Nordisk in 2014

30-01-2015

Danish diabetes care giant Novo Nordisk posted financials this morning, showing that sales for full-year…

DiabetesFinancialNovo NordiskPharmaceutical

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

23-01-2015

Danish diabetes care giant Novo Nordisk revealed yesterday that the European Medicines Agency’s Committee…

DiabetesEuropeMetabolicsNovo NordiskPharmaceuticalRegulationSaxenda

Novo Nordisk chooses Switzerland as first country to launch Xultophy

Novo Nordisk chooses Switzerland as first country to launch Xultophy

19-01-2015

Danish diabetes care giant Novo Nordisk has launched Xultophy (IDegLira) for people with type 2 diabetes…

DiabetesMarkets & MarketingNovo NordiskPharmaceuticalSwitzerlandXultophy

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

12-12-2014

The Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Society UK announced new funding…

CialisDiabetesEli LillyliraglutideMen's HealthNeurologicalNovo NordiskPharmaceuticalResearchTadalafilVictoza

CHMP positive opinion on Victoza in type 2 diabetes patients with moderate renal impairment

CHMP positive opinion on Victoza in type 2 diabetes patients with moderate renal impairment

21-11-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive…

DiabetesEuropeNovo NordiskPharmaceuticalRegulationVictoza

New Phase IIIa data further demonstrate benefits of liraglutide in obesity

04-11-2014

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

Novo Nordisk and Roche Diabetes Care launch new treatment option

Novo Nordisk and Roche Diabetes Care launch new treatment option

03-11-2014

Danish diabetes care giant Novo Nordisk has today launched NovoRapid PumpCart, the first pre-filled pump…

DiabetesMarkets & MarketingNovo NordiskNovoRapidPharmaceuticalRocheSwitzerland

Novo Nordisk begins building $130 million lab facility in Denmark

Novo Nordisk begins building $130 million lab facility in Denmark

31-10-2014

Danish insulin giant Novo Nordisk has made a 750 million Danish kroner ($130 million) investment in new…

DenmarkDiabetesNovo NordiskPharmaceuticalProduction

Novo Nordisk posts strong results, reassures with guidance

Novo Nordisk posts strong results, reassures with guidance

30-10-2014

Global diabetes care giant, Denmark’s Novo Nordisk saw its shares gain 4% to 265.80 Danish kroner this…

DiabetesFinancialNovo NordiskPharmaceutical

Novo Nordisk subpoenaed by US Attorney

Novo Nordisk subpoenaed by US Attorney

25-10-2014

Danish diabetes care giant Novo Nordis on Friday revealed it had been served with a subpoena by the office…

DenmarkDiabetesLegalNovo NordiskPharmaceuticalProductionUSA

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

08-10-2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential…

AdociaBioChaperoneDiabetesFIAspGlobalMarkets & MarketingNovo NordiskPharmaceuticalResearch

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

19-09-2014

The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent…

DenmarkDiabetesEuropeMexicoNovo NordiskPharmaceuticalResearchRyzodegTresibaXultophy

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

16-09-2014

Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today,…

DiabetesNovo NordiskPharmaceuticalResearchTresiba

The FDA publishes Novo Nordisk briefing documents ahead of Saxenda Advisory Committee meeting

The FDA publishes Novo Nordisk briefing documents ahead of Saxenda Advisory Committee meeting

09-09-2014

The US Food and Drug Administration has published briefing documents on Danish insulin giant Novo Nordisk’s…

Anti-diabetic drugsDiabetesliraglutideNovo NordiskPharmaceuticalRegulationTreatment of obesityUSA

Mexico first country to launch Novo Nordisk’s Ryzodeg

Mexico first country to launch Novo Nordisk’s Ryzodeg

01-09-2014

Danish diabetes care giant Novo Nordisk today announced that Mexico has become the first country in the…

DiabetesMarkets & MarketingMexicoNovo NordiskPharmaceuticalRyzodeg

Novo Nordisk accepts fine from Danish public prosecutor over financial disclosure

Novo Nordisk accepts fine from Danish public prosecutor over financial disclosure

18-08-2014

Danish insulin giant Novo Nordisk has accepted a fine of 500,000 kroner ($89,735), imposed by the Public…

CopenhagenDanish Financial Supervisory AuthorityDenmarkDiabetesFinancialNovo NordiskPharmaceutical

Positive new Ph III data with Novo Nordisk’s Xultophy

Positive new Ph III data with Novo Nordisk’s Xultophy

11-08-2014

Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchXultophy

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

08-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGerman Institute for Quality and EfficiencyGermanyNovo NordiskPharmaceuticalPricingRegulationTresiba

Novo Nordisk beats estimates as net profit grows 4%

Novo Nordisk beats estimates as net profit grows 4%

07-08-2014

Danish diabetes care giant Novo Nordisk released first-half 2014 financial results this morning, showing…

Business FinanceChief executiveDiabetesFinancialNOKNovo NordiskPeptide hormonesPharmaceuticalRecombinant proteins

Existing diabetes drug Victoza could be effective treatment for world’s obese

Existing diabetes drug Victoza could be effective treatment for world’s obese

06-08-2014

Pharmaceutical companies are racing to find a new form of obesity drug as patient numbers spiral and…

Anti-diabetic drugsDiabetesGastro-intestinalsGlobalMarkets & MarketingNovo NordiskPeptide hormonesPharmaceuticalVictoza

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

1 to 25 of 101 results

COMPANY SPOTLIGHT

Menarini

Back to top